The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
In a major crackdown, the US Food and Drug Administration (FDA) has been conducting an increased number of inspections of pharmaceutical manufacturing facilities in India. 7 December 2023
Ireland and USA-based natural killer (NK) cell therapy biotech ONK Therapeutics and US firm NAYA Biosciences have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. 6 December 2023
Massachusetts, USA-based cell therapy specialist Abcuro today announced the appointment of Mark Pruzanski as chairman of its board of directors. 6 December 2023
The US Food and Drug Administration (FDA) has approved Fabhalta (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). 6 December 2023
Swiss pharma giant Novartis is consolidating its commitment to radioligand therapies with the establishment of a second production site in China. 6 December 2023
Aqemia, a next-gen French pharmatech company leveraging artificial intelligence and quantum physics, has entered into a multi-year research collaboration with French pharma major Sanofi. 6 December 2023
American healthcare giant Johnson & Johnson has undertaken an in-depth business review, publishing plans which include the launch of 20 new products by the end of the decade. 6 December 2023
Neurocrine Biosciences yesterday revealed it has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for crinecerfont in congenital adrenal hyperplasia. 6 December 2023
Israel-based Teva Pharmaceutical Industries presented post hoc analysis of two Phase III studies at the European Headache Congress, showing the effectiveness of its already marketed migraine prevention treatment Ajovy (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. 6 December 2023
French drugmaker Sanofi is experiencing serious problems in Russia, as due to logistical problems, the company almost stopped exporting insulin from its Russian plant to the European Union. 6 December 2023
Germany-based Thermosome, a drug development company specializing in targeted tumor therapies, has named Frank Hermann as chief medical officer (CMO). 5 December 2023
Specialty biopharma firm Emergent BioSolutions has been awarded a $75 million option under an existing agreement with the Biomedical Advanced Research and Development Authority (BARDA). 5 December 2023
USA-based ophthalmic diseases specialist EyePoint Pharmaceuticals saw its shares leap as much as 212% yesterday, after it announced positive top-line results of its Phase II DAVIO 2 trial of EYP-1901. 5 December 2023
Shares of UK-based cancer and women’s health drug developer ValiRx were up 16.6% at 11.51 pence mid-afternoon, following the announcement that its joint venture company ValiSeek has entered a deal to license VAL401 to Ambrose Healthcare 5 December 2023
Johnson & Johnson’s TAR-200 has been granted Breakthrough Therapy designation (BTD) to potentially treat patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for or elected not to undergo radical cystectomy. 5 December 2023
French independent pharma major Servier today announced the appointment of Nicolas Garnier as chief patient officer, effective from December 4. 5 December 2023
Japan’s largest drugmaker Takeda has announced the signing of a three-year memorandum of understanding (MoU) with the Biotechnology Industry Research Assistance Council (BIRAC). 5 December 2023